Cargando…

An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors

Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' si...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Bar, Hend Mohamed, Walters, Adam A, Lim, Yau, Rouatbi, Nadia, Qin, Yue, Gheidari, Fatemeh, Han, Shunping, Osman, Rihab, Wang, Julie Tzu-Wen, Al-Jamal, Khuloud T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419059/
https://www.ncbi.nlm.nih.gov/pubmed/34522209
http://dx.doi.org/10.7150/thno.56936
_version_ 1783748680796340224
author Abdel-Bar, Hend Mohamed
Walters, Adam A
Lim, Yau
Rouatbi, Nadia
Qin, Yue
Gheidari, Fatemeh
Han, Shunping
Osman, Rihab
Wang, Julie Tzu-Wen
Al-Jamal, Khuloud T.
author_facet Abdel-Bar, Hend Mohamed
Walters, Adam A
Lim, Yau
Rouatbi, Nadia
Qin, Yue
Gheidari, Fatemeh
Han, Shunping
Osman, Rihab
Wang, Julie Tzu-Wen
Al-Jamal, Khuloud T.
author_sort Abdel-Bar, Hend Mohamed
collection PubMed
description Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant 'don't eat me' marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 ±6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies.
format Online
Article
Text
id pubmed-8419059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-84190592021-09-13 An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors Abdel-Bar, Hend Mohamed Walters, Adam A Lim, Yau Rouatbi, Nadia Qin, Yue Gheidari, Fatemeh Han, Shunping Osman, Rihab Wang, Julie Tzu-Wen Al-Jamal, Khuloud T. Theranostics Research Paper Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant 'don't eat me' marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 ±6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies. Ivyspring International Publisher 2021-08-11 /pmc/articles/PMC8419059/ /pubmed/34522209 http://dx.doi.org/10.7150/thno.56936 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Abdel-Bar, Hend Mohamed
Walters, Adam A
Lim, Yau
Rouatbi, Nadia
Qin, Yue
Gheidari, Fatemeh
Han, Shunping
Osman, Rihab
Wang, Julie Tzu-Wen
Al-Jamal, Khuloud T.
An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title_full An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title_fullStr An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title_full_unstemmed An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title_short An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
title_sort “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419059/
https://www.ncbi.nlm.nih.gov/pubmed/34522209
http://dx.doi.org/10.7150/thno.56936
work_keys_str_mv AT abdelbarhendmohamed aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT waltersadama aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT limyau aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT rouatbinadia aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT qinyue aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT gheidarifatemeh aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT hanshunping aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT osmanrihab aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT wangjulietzuwen aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT aljamalkhuloudt aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT abdelbarhendmohamed eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT waltersadama eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT limyau eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT rouatbinadia eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT qinyue eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT gheidarifatemeh eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT hanshunping eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT osmanrihab eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT wangjulietzuwen eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors
AT aljamalkhuloudt eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors